Opthea, which ended June with 34 full-time employees, is laying off staff to reduce its spending. Once the workforce reduction is complete, which Opthea expects to happen May 1, the biotech said it will have “a limited number of employees” who it is keeping on “to ensure the compliant termination of clinical trial activities and oversee administration operations.
https://www.fiercebiotech.com/biotech/opthea-lays-65-staff-after-back-back-phase-3-flops